Navigation Links
GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
Date:12/20/2007

information on investigational therapies for chronic ITP patients. Two pivotal trials, one Phase III trial and one Phase II trial, were submitted to support the NDA submission.

About the Phase III Data(3)

The Phase III study was an international, randomized, double-blind, placebo-controlled trial that enrolled 114 adults with chronic ITP and baseline platelet counts of less than 30,000/microliter. The primary endpoint in this study was a platelet count of greater than or equal to 50,000/microliter after up to six weeks of therapy. An endpoint of 50,000/microliter was selected because at a platelet count of greater than 50,000/microliter patients have a low risk of bleeding and bruising. Eligible patients must have had a platelet count less than 30,000/microliter, had failed or stopped responding to one or more chronic ITP therapies such as corticosteroids, immunoglobulins and/or splenectomy. Patients were allowed to continue on a concomitant chronic ITP medication, provided their dose had been stable for at least a month prior to enrollment. These patients were randomized to either placebo or eltrombopag 50mg (76 patients) once daily for up to six weeks. Patients were assessed for platelet count weekly and for six weeks following discontinuation of treatment with eltrombopag. Bleeding events were assessed weekly using the World Health Organization (WHO) bleeding scale. The study was originally presented by investigator Drew Provan, M.D., Senior Lecturer in Haematology, Department of Haematology, Royal London Hospital, U.K. at the 2007 Congress of the European Hematology Association in Vienna, Austria.

At the end of the trial, 59% of eltrombopag treated patients on the 50mg dose and 16% of placebo treated patients achieved a platelet count of greater than or equal to 50,000/microliter. Importantly, there was a significantly lower incidence of bleeding during treatment with eltrombopag compared to placebo (p=0.029). Clinically significant seri
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
11. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... (PRWEB) May 25, 2013 Life science ... are used to detect and create a new substance ... reading and are also known as biotechnology reagents. Such ... diagnosis and education. , This market is driven by ... in the field of therapeutics, growth in research and ...
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... a federal multidistrict litigation underway in U.S. District Court, ... Liebhard LLP reports. According to a Case Management ... procedures that govern the filing of contested motions in ... for filing those motions. (In re: Actos Product Liability ...
(Date:5/25/2013)... May 25, 2013 The report ... By Types, Functions, Applications, Ingredients, Shell Materials, Packaging, ... the global food encapsulation market with analysis and ... It also identifies the driving and restraining factors ... of trends, opportunities, and challenges. The market is ...
(Date:5/25/2013)... MO (PRWEB) May 25, 2013 Providing patients ... the Diet Doc team of weight management professionals. But, aside ... and effectively, Diet Doc’s hCG diets also ... like abuse during childhood like bullying, more control over their ... capable of dealing with the underlying factors of weight gain ...
(Date:5/25/2013)... Pradaxa lawsuits filed on behalf ... bleeding while using the blood thinner continue to mount in ... of Illinois, Bernstein Liebhard LLP reports. According to a ... had been filed in the litigation as of ... by the Court on May 15th. ( In Re: Pradaxa ...
Breaking Medicine News(10 mins):Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3
... Research Group, Inc. released TreatmentTrends(R): US Nephrology, a syndicated ... US Nephrologists.In the ESA market, changes that have occurred ... while the overall use of ESAs has remained stable ... patients with Chronic Kidney Disease not on dialysis (CKD), ...
... Mexico, April 27 Grupo Aeroportuario del Pacifico, S.A.B. de ... or "GAP" today announced the following:On Sunday, April 26, 2009, ... A and B viruses in humans as well as the ... (Swine Flu Virus). As a result of the alerts, the ...
... - On Tuesday, April 28, at 10:00 a.m., Donate Life, ... donors, and family members of organ ... Sacramento area firefighters at the California Firefighters, ... by Senator George Runner and Senator ...
... sudden and near-constant stream of news reports about swine ... These reactions are understandable because circumstances are rapidly evolving ... during this period of uncertainty, you can take several ... outlook. The American Psychological Association has useful information and ...
... Innovations, Inc. (Nasdaq: YDNT ) today announced results ... the first quarter of 2009 were $23.8 million, a decrease ... in the first quarter of 2008. Income from operations increased ... from $4.6 million in the first quarter of 2008. Net ...
... April 27 Hanger Orthopedic Group, Inc. (NYSE: ... quarter ended March 31, 2009, an increase of $11.4 million, ... Net income increased $0.9 million, or 26.6%, to $4.5 million ... year. Net income applicable to common stock in the ...
Cached Medicine News:Health News:Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group 2Health News:Grupo Aeroportuario del Pacifico, S.A.B. de C.V. Announcement Regarding Swine Flu Virus 2Health News:Grupo Aeroportuario del Pacifico, S.A.B. de C.V. Announcement Regarding Swine Flu Virus 3Health News:Donate Life California to Hold Press Conference Commemorating Donation Heroes Tuesday, April 28, 10:00 a.m., State Capitol 2Health News:APA Offers Tips on Managing Anxiety About Swine Flu 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 5Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 6Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 2Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 3Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 4Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 5Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 6
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical ... nurse triage and nurse advice lines, announces its ... comprising physician, nursing and administrative leaders, provides clinical ... quality and cost-effective services for hospital clients, physician ... national healthcare system evolves, it,s imperative to continuously ...
(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...
(Date:5/23/2013)... , May 23, 2013 Anthem Blue ... that would have required them to obtain their medications ... Consumer Watchdog and Whatley Kallas LLC.  ... Court, alleged that Blue Cross,s mandatory mail order program ... their health and privacy. "This settlement brings ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
Blood sedimentation rate analysis...
... speed and precision in a flexible ... technology. With its advanced design, ... to 300 samples or 500 tests ... This high performance, fully automated analyzer ...
... lancing device that has set the standard ... This re-usable lancing device assists in obtaining ... is constructed in the USA of durable ... year after year. It's the only lancing ...
... of testing. Unlike conventional lancing systems, the ... one with a six-lancet drum. It offers ... and improved safety. With 11 depth settings ... for less skin tearing, over 90% of ...
Medicine Products: